KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Other Non-Current Liabilities (2016 - 2025)

Astrazeneca has reported Other Non-Current Liabilities over the past 11 years, most recently at $85.0 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 90.77% year-over-year to $85.0 million; the TTM value through Dec 2025 reached $85.0 million, down 90.77%, while the annual FY2025 figure was $85.0 million, 90.77% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $85.0 million at Astrazeneca, down from $921.0 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $4.3 billion in Q4 2022 and troughed at $85.0 million in Q4 2025.
  • A 5-year average of $1.7 billion and a median of $1.2 billion in 2023 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 111.81% in 2022 and later tumbled 90.77% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $2.0 billion in 2021, then skyrocketed by 111.81% to $4.3 billion in 2022, then crashed by 72.58% to $1.2 billion in 2023, then decreased by 21.35% to $921.0 million in 2024, then tumbled by 90.77% to $85.0 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for AZN at $85.0 million in Q4 2025, $921.0 million in Q4 2024, and $1.2 billion in Q4 2023.